1 | diabetes | 39,734 |
2 | integrons | 47 |
3 | corns | 14 |
4 | pmr/day | 5 |
5 | years-of-life | 5 |
6 | ',3 | 4 |
7 | cblc | 4 |
8 | left-handers | 4 |
9 | ml-ampoules | 4 |
10 | preincentive | 4 |
11 | prophyla* | 4 |
12 | treponemes | 4 |
13 | atherosclerotics | 3 |
14 | chd/diabetes | 3 |
15 | exacerbations/year | 3 |
16 | infectiologist | 3 |
17 | kiwifruit/d | 3 |
18 | mg/k | 3 |
19 | tabl | 3 |
20 | borderline-tumors | 2 |
21 | bretz | 2 |
22 | dermatocorticosteroid | 2 |
23 | diabetes.. | 2 |
24 | diaphane | 2 |
25 | e2-17-o-glucuronide | 2 |
26 | electrotherapies | 2 |
27 | emotion-focussed | 2 |
28 | fbcc | 2 |
29 | gy/tbi | 2 |
30 | hpv53 | 2 |
31 | indeterminates | 2 |
32 | levinea | 2 |
33 | luteotropin | 2 |
34 | lymphostasis | 2 |
35 | mg/kg+methotrexate | 2 |
36 | mg/q8h | 2 |
37 | nonexpressing | 2 |
38 | thoracoscopes | 2 |
39 | °c/day | 2 |
40 | μmol·kg−¹·min−¹ | 2 |
41 | -antiplasmin | 1 |
42 | 081.65 | 1 |
43 | 1/2-fold | 1 |
44 | 242.14 | 1 |
45 | 360±390 | 1 |
46 | 5'-helices | 1 |
47 | alloxan-diabetes | 1 |
48 | alpha-difluoromethyl-ornithine | 1 |
49 | alpha-hydroxy-12beta-hydroxy-isopimara-8 | 1 |
50 | alpha/chop | 1 |
51 | aspects-specimens | 1 |
52 | bottles/d | 1 |
53 | c-radicals | 1 |
54 | cells/vs | 1 |
55 | clients/week | 1 |
56 | cm/years | 1 |
57 | control/3 | 1 |
58 | copies/pcr | 1 |
59 | corticosteroid-avoidance | 1 |
60 | cpru-μ-cn-rucp | 1 |
61 | crossed-factorial | 1 |
62 | day-experiment | 1 |
63 | decapitations | 1 |
64 | diabeters | 1 |
65 | diabetus | 1 |
66 | dimethoxy-5,6-dihydroxy-9,10-dihydrophenanthrene | 1 |
67 | dipterans | 1 |
68 | endometrioses | 1 |
69 | enhancins | 1 |
70 | ere-construct | 1 |
71 | erythro-couperosis | 1 |
72 | family-planning/postnatal | 1 |
73 | feverall | 1 |
74 | fingerbreadths | 1 |
75 | fixed-workload | 1 |
76 | flare/cells | 1 |
77 | forceplates | 1 |
78 | fossella | 1 |
79 | g.o.d | 1 |
80 | g/i.v./infusion | 1 |
81 | gbsd | 1 |
82 | genotypes-neither | 1 |
83 | glutaraldhyde | 1 |
84 | groups/protocol | 1 |
85 | gy/fr | 1 |
86 | gy/s | 1 |
87 | gy×20 | 1 |
88 | h-azirines | 1 |
89 | h-ppg | 1 |
90 | half-lines | 1 |
91 | inhibiters | 1 |
92 | insulin-dependent-diabetes | 1 |
93 | iso-thermexes | 1 |
94 | kg/patient | 1 |
95 | levels/follicle | 1 |
96 | mg/kgbw/h | 1 |
97 | mg/ml*min | 1 |
98 | microcarcinomata-3 | 1 |
99 | midforearm | 1 |
100 | ministrokes | 1 |
101 | ml·kg· | 1 |
102 | mmhg/ms | 1 |
103 | months=4.0±0.7 | 1 |
104 | months=4.1±0.9 | 1 |
105 | n-acetylglucosaminyltransferase-l:1 | 1 |
106 | n-acetylglucosaminyltransferase-m | 1 |
107 | nct00252694 | 1 |
108 | non-experienced-residents | 1 |
109 | non-insulin-dependent-diabetes | 1 |
110 | non-l-thyroxine | 1 |
111 | noninsulindependent-diabetes | 1 |
112 | obesity/ | 1 |
113 | pachymeters | 1 |
114 | paraproteinemia | 1 |
115 | pee-rpee | 1 |
116 | pens/room | 1 |
117 | point-improvement | 1 |
118 | positive-patients | 1 |
119 | postburn-hours | 1 |
120 | powermeters | 1 |
121 | rating-point | 1 |
122 | relapses/reinfections | 1 |
123 | run- | 1 |
124 | sachets/d | 1 |
125 | sciatic/femoral | 1 |
126 | self-help-based | 1 |
127 | sets·d-1 | 1 |
128 | small-town/rural | 1 |
129 | study-diabetes | 1 |
130 | tablets/h | 1 |
131 | teflon-insulated | 1 |
132 | theromocouples | 1 |
133 | timothy- | 1 |
134 | treatments-standard | 1 |
135 | truepositive | 1 |
136 | unilaterals | 1 |
137 | vessels/mm2 | 1 |
138 | ways-fibrinolysis | 1 |
139 | wk-interval | 1 |
140 | x/d | 1 |
141 | year-disease | 1 |
142 | µg/mnl | 1 |
143 | µg·kg·h | 1 |
144 | α-agarase | 1 |
1 | ',3 | 4 |
2 | -antiplasmin | 1 |
3 | 081.65 | 1 |
4 | 1/2-fold | 1 |
5 | 242.14 | 1 |
6 | 360±390 | 1 |
7 | 5'-helices | 1 |
8 | alloxan-diabetes | 1 |
9 | alpha-difluoromethyl-ornithine | 1 |
10 | alpha-hydroxy-12beta-hydroxy-isopimara-8 | 1 |
11 | alpha/chop | 1 |
12 | aspects-specimens | 1 |
13 | atherosclerotics | 3 |
14 | borderline-tumors | 2 |
15 | bottles/d | 1 |
16 | bretz | 2 |
17 | c-radicals | 1 |
18 | cblc | 4 |
19 | cells/vs | 1 |
20 | chd/diabetes | 3 |
21 | clients/week | 1 |
22 | cm/years | 1 |
23 | control/3 | 1 |
24 | copies/pcr | 1 |
25 | corns | 14 |
26 | corticosteroid-avoidance | 1 |
27 | cpru-μ-cn-rucp | 1 |
28 | crossed-factorial | 1 |
29 | day-experiment | 1 |
30 | decapitations | 1 |
31 | dermatocorticosteroid | 2 |
32 | diabeters | 1 |
33 | diabetes | 39,734 |
34 | diabetes.. | 2 |
35 | diabetus | 1 |
36 | diaphane | 2 |
37 | dimethoxy-5,6-dihydroxy-9,10-dihydrophenanthrene | 1 |
38 | dipterans | 1 |
39 | e2-17-o-glucuronide | 2 |
40 | electrotherapies | 2 |
41 | emotion-focussed | 2 |
42 | endometrioses | 1 |
43 | enhancins | 1 |
44 | ere-construct | 1 |
45 | erythro-couperosis | 1 |
46 | exacerbations/year | 3 |
47 | family-planning/postnatal | 1 |
48 | fbcc | 2 |
49 | feverall | 1 |
50 | fingerbreadths | 1 |
51 | fixed-workload | 1 |
52 | flare/cells | 1 |
53 | forceplates | 1 |
54 | fossella | 1 |
55 | g.o.d | 1 |
56 | g/i.v./infusion | 1 |
57 | gbsd | 1 |
58 | genotypes-neither | 1 |
59 | glutaraldhyde | 1 |
60 | groups/protocol | 1 |
61 | gy/fr | 1 |
62 | gy/s | 1 |
63 | gy/tbi | 2 |
64 | gy×20 | 1 |
65 | h-azirines | 1 |
66 | h-ppg | 1 |
67 | half-lines | 1 |
68 | hpv53 | 2 |
69 | indeterminates | 2 |
70 | infectiologist | 3 |
71 | inhibiters | 1 |
72 | insulin-dependent-diabetes | 1 |
73 | integrons | 47 |
74 | iso-thermexes | 1 |
75 | kg/patient | 1 |
76 | kiwifruit/d | 3 |
77 | left-handers | 4 |
78 | levels/follicle | 1 |
79 | levinea | 2 |
80 | luteotropin | 2 |
81 | lymphostasis | 2 |
82 | mg/k | 3 |
83 | mg/kg+methotrexate | 2 |
84 | mg/kgbw/h | 1 |
85 | mg/ml*min | 1 |
86 | mg/q8h | 2 |
87 | microcarcinomata-3 | 1 |
88 | midforearm | 1 |
89 | ministrokes | 1 |
90 | ml-ampoules | 4 |
91 | ml·kg· | 1 |
92 | mmhg/ms | 1 |
93 | months=4.0±0.7 | 1 |
94 | months=4.1±0.9 | 1 |
95 | n-acetylglucosaminyltransferase-l:1 | 1 |
96 | n-acetylglucosaminyltransferase-m | 1 |
97 | nct00252694 | 1 |
98 | non-experienced-residents | 1 |
99 | non-insulin-dependent-diabetes | 1 |
100 | non-l-thyroxine | 1 |
101 | nonexpressing | 2 |
102 | noninsulindependent-diabetes | 1 |
103 | obesity/ | 1 |
104 | pachymeters | 1 |
105 | paraproteinemia | 1 |
106 | pee-rpee | 1 |
107 | pens/room | 1 |
108 | pmr/day | 5 |
109 | point-improvement | 1 |
110 | positive-patients | 1 |
111 | postburn-hours | 1 |
112 | powermeters | 1 |
113 | preincentive | 4 |
114 | prophyla* | 4 |
115 | rating-point | 1 |
116 | relapses/reinfections | 1 |
117 | run- | 1 |
118 | sachets/d | 1 |
119 | sciatic/femoral | 1 |
120 | self-help-based | 1 |
121 | sets·d-1 | 1 |
122 | small-town/rural | 1 |
123 | study-diabetes | 1 |
124 | tabl | 3 |
125 | tablets/h | 1 |
126 | teflon-insulated | 1 |
127 | theromocouples | 1 |
128 | thoracoscopes | 2 |
129 | timothy- | 1 |
130 | treatments-standard | 1 |
131 | treponemes | 4 |
132 | truepositive | 1 |
133 | unilaterals | 1 |
134 | vessels/mm2 | 1 |
135 | ways-fibrinolysis | 1 |
136 | wk-interval | 1 |
137 | x/d | 1 |
138 | year-disease | 1 |
139 | years-of-life | 5 |
140 | °c/day | 2 |
141 | µg/mnl | 1 |
142 | µg·kg·h | 1 |
143 | α-agarase | 1 |
144 | μmol·kg−¹·min−¹ | 2 |
1 | prophyla* | 4 |
2 | run- | 1 |
3 | timothy- | 1 |
4 | diabetes.. | 2 |
5 | obesity/ | 1 |
6 | gy×20 | 1 |
7 | 360±390 | 1 |
8 | sets·d-1 | 1 |
9 | n-acetylglucosaminyltransferase-l:1 | 1 |
10 | vessels/mm2 | 1 |
11 | ',3 | 4 |
12 | microcarcinomata-3 | 1 |
13 | control/3 | 1 |
14 | hpv53 | 2 |
15 | 242.14 | 1 |
16 | nct00252694 | 1 |
17 | 081.65 | 1 |
18 | months=4.0±0.7 | 1 |
19 | alpha-hydroxy-12beta-hydroxy-isopimara-8 | 1 |
20 | months=4.1±0.9 | 1 |
21 | levinea | 2 |
22 | paraproteinemia | 1 |
23 | fossella | 1 |
24 | fbcc | 2 |
25 | cblc | 4 |
26 | g.o.d | 1 |
27 | bottles/d | 1 |
28 | sachets/d | 1 |
29 | kiwifruit/d | 3 |
30 | x/d | 1 |
31 | fixed-workload | 1 |
32 | self-help-based | 1 |
33 | emotion-focussed | 2 |
34 | teflon-insulated | 1 |
35 | dermatocorticosteroid | 2 |
36 | 1/2-fold | 1 |
37 | treatments-standard | 1 |
38 | gbsd | 1 |
39 | corticosteroid-avoidance | 1 |
40 | e2-17-o-glucuronide | 2 |
41 | glutaraldhyde | 1 |
42 | pee-rpee | 1 |
43 | years-of-life | 5 |
44 | levels/follicle | 1 |
45 | diaphane | 2 |
46 | dimethoxy-5,6-dihydroxy-9,10-dihydrophenanthrene | 1 |
47 | alpha-difluoromethyl-ornithine | 1 |
48 | non-l-thyroxine | 1 |
49 | year-disease | 1 |
50 | α-agarase | 1 |
51 | mg/kg+methotrexate | 2 |
52 | truepositive | 1 |
53 | preincentive | 4 |
54 | nonexpressing | 2 |
55 | h-ppg | 1 |
56 | tablets/h | 1 |
57 | mg/kgbw/h | 1 |
58 | mg/q8h | 2 |
59 | µg·kg·h | 1 |
60 | gy/tbi | 2 |
61 | mg/k | 3 |
62 | clients/week | 1 |
63 | crossed-factorial | 1 |
64 | sciatic/femoral | 1 |
65 | small-town/rural | 1 |
66 | family-planning/postnatal | 1 |
67 | wk-interval | 1 |
68 | tabl | 3 |
69 | feverall | 1 |
70 | µg/mnl | 1 |
71 | groups/protocol | 1 |
72 | n-acetylglucosaminyltransferase-m | 1 |
73 | pens/room | 1 |
74 | midforearm | 1 |
75 | mg/ml*min | 1 |
76 | -antiplasmin | 1 |
77 | luteotropin | 2 |
78 | g/i.v./infusion | 1 |
79 | cpru-μ-cn-rucp | 1 |
80 | alpha/chop | 1 |
81 | exacerbations/year | 3 |
82 | copies/pcr | 1 |
83 | genotypes-neither | 1 |
84 | gy/fr | 1 |
85 | gy/s | 1 |
86 | atherosclerotics | 3 |
87 | 5'-helices | 1 |
88 | electrotherapies | 2 |
89 | ministrokes | 1 |
90 | theromocouples | 1 |
91 | ml-ampoules | 4 |
92 | treponemes | 4 |
93 | half-lines | 1 |
94 | h-azirines | 1 |
95 | thoracoscopes | 2 |
96 | endometrioses | 1 |
97 | forceplates | 1 |
98 | indeterminates | 2 |
99 | diabetes | 39,734 |
100 | alloxan-diabetes | 1 |
101 | insulin-dependent-diabetes | 1 |
102 | non-insulin-dependent-diabetes | 1 |
103 | noninsulindependent-diabetes | 1 |
104 | study-diabetes | 1 |
105 | chd/diabetes | 3 |
106 | iso-thermexes | 1 |
107 | fingerbreadths | 1 |
108 | lymphostasis | 2 |
109 | erythro-couperosis | 1 |
110 | ways-fibrinolysis | 1 |
111 | c-radicals | 1 |
112 | unilaterals | 1 |
113 | flare/cells | 1 |
114 | mmhg/ms | 1 |
115 | dipterans | 1 |
116 | aspects-specimens | 1 |
117 | enhancins | 1 |
118 | decapitations | 1 |
119 | relapses/reinfections | 1 |
120 | integrons | 47 |
121 | corns | 14 |
122 | cm/years | 1 |
123 | left-handers | 4 |
124 | diabeters | 1 |
125 | powermeters | 1 |
126 | pachymeters | 1 |
127 | inhibiters | 1 |
128 | borderline-tumors | 2 |
129 | postburn-hours | 1 |
130 | non-experienced-residents | 1 |
131 | positive-patients | 1 |
132 | diabetus | 1 |
133 | cells/vs | 1 |
134 | ere-construct | 1 |
135 | kg/patient | 1 |
136 | point-improvement | 1 |
137 | day-experiment | 1 |
138 | rating-point | 1 |
139 | infectiologist | 3 |
140 | °c/day | 2 |
141 | pmr/day | 5 |
142 | bretz | 2 |
143 | ml·kg· | 1 |
144 | μmol·kg−¹·min−¹ | 2 |